Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2001

View Archived Issues

PDL grants license to Celltech for humanized anti-TNF antibodies

Xenon Genetics discovers two new drug targets for metabolic and neurological diseases

Worldwide expansion of Merck/Schering-Plough cholesterol partnership

Asimadoline alters cytokine gene expression in adjuvant arthritis

TAS-108 well tolerated and readily absorbed after oral dosing in preliminary clinical trial

CS-758: a new triazole antifungal agent with promise for candidiasis and aspergillosis

SkyePharma withdraws Solaraze termination notice

Cytovax files for approval to begin human trials of Cytovaxine

Clarinex cleared by FDA for SAR symptom relief, will be launched next month

New option for early-stage prostate cancer receives FDA clearance

Thalomid granted orphan drug status in Europe for multiple myeloma and ENL

Orally active growth hormone secretagogue SM-130686 identified by Sumitomo

Amgen initiates phase III AMG-073 trial for hyperparathyroidism

IL-12 gene therapy studied in Japan for inducing tumor immunity

Phase I trial initiated for antithrombotic drug candidate GH-9001

GSK discontinues development of ADL-2-1294

Potent new MMP inhibitor has excellent oral activity in a rat collagen degradation model

Forest submits NDA for oxycodone/ibuprofen to treat moderate to severe pain

Myriad Genetics seeks clearance for new clinical trial of Flurizan

Companies collaborate in developing neuroprotective compound DD-612

Superior efficacy of triple-antigen hepatitis B vaccine confirmed in inadequate responders

Avigen receives FDA approval to continue clinical trials for Coagulin-B gene therapy

New series from Bayer with excellent antiallergic activity

Lipase inhibitors produced by Streptomyces

CRF antagonists from a series of tricyclic fused pyrimidine and pyridine derivatives

Korean researchers identify new CDK inhibitors

Boston-based scientists disclose radiolabeled tumor imaging agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...